Who
Dean Y. Li
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals; Executive VP & President, MRL, Merck & Company.
In numbers
- Trades disclosed
- 113
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $9.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 26 Feb 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,378 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,747 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,747 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,885 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —58,207 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,885 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —58,207 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $520K4,722 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $256K2,326 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,722 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,722 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $520K4,722 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $256K2,326 at $110.03 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,268 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,268 at $0.00 | filing |
| 10 Feb 2026filed 10 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,235 at $117.52 | filing |
| 10 Feb 2026filed 10 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,235 at $117.52 | filing |
| 4 Feb 2026filed 6 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $845K15,087 at $56.04 | filing |
News
Merck's 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?MRK · insidermonkey.com · 19 Oct 2026AbbVie vs. Merck: Which Pharma Stock Offers Better Value?MRK · insidermonkey.com · 16 Oct 2026Merck's Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?MRK · insidermonkey.com · 16 Oct 2026
0 headlines in the last 90 days name Dean Y. Li; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.